A Comparative Study on Monotherapy with Metformin, Vit-B3, Vit- D, Chromium Piconilate and Lifestyle Modification in development of Type II Diabetes Mellitus in the Metabolic Syndrome Patients

  • Sanjay Banjare Assistant Professor, Department. of of Pharmacology Govt Chhattisharh Institute of Medical Sciences, Bilaspur (C.G. )
  • Vinod Kapoor Professor and head, Department of Pharmacology, SGT Medical College, Gurgaon (H.R.)
Keywords: Diabetes Mellitus, Metabolic Syndrome, Metformin

Abstract

Background: Metabolic syndrome is a combination of multiple risk factors that increases an individual chance of developing cardiovascular or type II diabetes mellitus and most of people with metabolic syndrome have Insulin resistance, which elevates the risk of developing Type II diabetes mellitus. While the pathogenesis of the metabolic syndrome and each of its components is complex and not well understood, central obesity and insulin resistance are acknowledged as important causative factors. Most scrutinized literature was collected from different sources including PubMed. This study was carried out at Govt. Chhattisgarh Institute of medical sciences Bilaspur.

Aim: To compare the incidence of progression of metabolic syndrome into type II diabetes mellitus in patient who were put on one of the following treatments along with lifestyle modification :- Metformin, Chromium Piconilate ,Vitamin –D3 and Niacin (Vitamin. - B3).
Methods: The objective of this study recruited 250 patient, aged between 35 to 60 years, who fulfilled the inclusion and exclusion criteria of Metabolic syndrome as per study design.

Results: 250 Participants was enrolled during 3 years of the study. 125 (50 %) male and 125 (50 %) Female were found metabolic syndrome. A total (8%) of patient were found incidence of progression of metabolic syndrome into Type II Diabetes Mellitus. In different group as Metformin group-(0%), Niacin group (6%), Vit-D3 group (0%), Chromium Piconilate group (16 %) and (18%) in the lifestyle modification group.

Conclusions: Metformin and Vit- D3 can reverse the effects of metabolic syndrome due to its broad effects on many of the components of metabolic syndrome; thus preventing diabetes and heart disease.

Downloads

Download data is not yet available.

References

1. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome new worldwide defi nition. Lancet 2005;366:1059-62.
2. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation.Diabet Med - 2006 May;23(5):469-80.
3. www.idf.org/metabolic_syndrome, website of the International Diabetes Federation.
4. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37(12):1595-1607.
5. Stern M, Williams K, Gonzalez-Villalpando C et al. Does the metabolic syndrom improve identifi cation of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004;27(11):2676-81
6. Hu G, Qiao Q, Tuomilehto J et al. Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies. The DECODE Insulin Study Group. Diabetologia 2004;47:1245–56
7. Carr DB, Utzschneider KM, Hull RL et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004;53(8):2087-94
8. Saad MF, Lillioja S, Nyomba BL et al. Racial differences in the relation between blood pressure and insulin resistance. New England Journal of Medicine 1991;324:733-9
9. Anderson PJ, Critchley JAJH, Chan JCN et al. Factor analysis of the metabolic syndrome: obesity vs insulin resistance as the central abnormality. International Journal of Obesity 2001;25:1782
10. Rexrode KM, Carey VJ, Hennekens CH et al. Abdominal adiposity and coronary heart disease in women. JAMA 1998;280:1843-8.
11. Diabetes and Obesity: Time to Act. International Diabetes Federation (IDF) and International Association for the Study of Obesity (IASO), 2004.
12. Nakamura T, Tokunga K, ShimomuraI et al. Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 1994;107:239-46
13. Bonora E, Kiechl S, Willeit J et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998;47(10):1643-9
14. Nesto RW. The relation of insulin resistance syndromes to risk of
cardiovascular disease. Rev Cardiovasc Med 2003;4(6):S11-S18
15. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med
1998; 15(7):539-553.
16. International Diabetes Federation. The IDF consensus worldwide definition
of the metabolic syndrome: Part 1: Worldwide definition for use in clinical
practice. 2005. Ref Type: Internet Communication
17. Nagalaski A, Bryla J. Niacin in therapy. Postepy Hig Med Dosw. (Online)
2007;15(61):288-302.
18. Cefalu WT, Hu FB. Role of chromium in human health and in diabetes.
Diabetes Care 2004;27:2741–2751.
Published
2019-09-30
How to Cite
1.
Banjare S, Kapoor V. A Comparative Study on Monotherapy with Metformin, Vit-B3, Vit- D, Chromium Piconilate and Lifestyle Modification in development of Type II Diabetes Mellitus in the Metabolic Syndrome Patients. Int Arch BioMed Clin Res [Internet]. 2019Sep.30 [cited 2019Dec.7];5(3):74-6. Available from: http://iabcr.org/index.php/iabcr/article/view/505
Section
ORIGINAL ARTICLES ~ Pharmacology